Continue

Improving Lives, Restoring Hope

At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.

How We’re Making a Difference

Improving Lives, Restoring Hope

At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.

How We’re Making a Difference

Improving Lives, Restoring Hope

At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.

How We’re Making a Difference

Improving Lives, Restoring Hope

At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.

How We’re Making a Difference

Home

Welcome to Cerecor

Cerecor is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases.

About CNS

Learn more about the CNS disorders we’re targeting, as well as contact information for help hotlines.

Learn More About CNS Disorders

Backed by More Than 100 Collective Years of Experience

The members of our team have extensive pharmaceutical product development and commercialization experience and have played key roles in the development or commercialization of Prozac®, Zyprexa®, Cymbalta®, Nuplazid™ and Abilify®.

View Management Team
Uli Hacksell, Ph.D.

Uli Hacksell, Ph.D.

Chief Executive Officer, President, and Chairman of the Board of Directors

Dr. Hacksell was appointed CEO & President of Cerecor Inc. in January of 2016. Dr. Hacksell also serves as Chairman of the Board of Directors, a position he has held since May of 2015. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery. Prior to ACADIA, Dr. Hacksell held various senior executive positions at Astra AB, or Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology, President of Astra Draco, one of Astra’s largest research and development subsidiaries, and Vice President of CNS Preclinical R&D at Astra Arcus, another Astra subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. Dr. Hacksell is currently Chairman of the Board of Directors of Glionova Therapeutics and is also a member of the Board of Directors of InDex Pharmaceuticals and Uppsala University. He received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University.

Ronald Marcus, M.D.

Ronald Marcus, M.D.

Chief Medical Officer and Head, Regulatory Affairs

Dr. Marcus has served as our Chief Medical Officer and Head of Regulatory Affairs since May 2015. He has more than 20 years of experience in the development of neuroscience drugs at both Spinifex Pharmaceuticals, or Spinifex, and Bristol-Myers Squibb. Dr. Marcus was most recently the Chief Medical Officer at Spinifex, where he was responsible for driving clinical development and regulatory strategy of its lead compound for neuropathic pain. Prior to that, Dr. Marcus held various positions at Bristol-Myers Squibb including Group Director of Neuroscience Strategic Unit and Executive Director of Neuroscience Global Clinical Research. In this role, he was Early Development Team Leader for neuropathic pain, schizophrenia and migraine compounds and Life-Cycle Management Team Leader for Abilify®, which included the development of Abilify® for the adjunctive treatment of depression. He has extensive experience in early drug development and possesses both breadth and depth in all of the key functional areas of exploratory and late development, disease biology and regulatory affairs. Dr. Marcus has been recognized within the biopharmaceutical industry for his excellence in overall drug development, innovative strategic leadership and executional excellence while spearheading an industry-leading life cycle management program for Abilify®. In addition to the approval of over 20 New Drug Applications (NDA) and supplemental NDAs globally for Abilify®, Dr. Marcus also led the successful development of Serzone®, an antidepressant. Further, Dr. Marcus has authored more than 80 peer-reviewed publications. Dr. Marcus received his B.A. in Psychology from the University of Virginia. He earned his M.D. from SUNY Buffalo and completed his psychiatry residency and the National Institute of Mental Health research fellowship at Cornell University, New York Hospital-Westchester Division.

Mariam E. Morris, CPA

Mariam E. Morris, CPA

Chief Financial Officer

Mariam E. Morris joined Cerecor Pharmaceuticals as Chief Financial Officer in 2015, leading Cerecor through its initial public offering and currently serves as the Company’s Secretary and Treasurer. Mariam is a seasoned financial executive and comes to Cerecor with over 20 years of experience and having owned her own consulting firm for the past six years. While consulting, Mariam worked with several business as out-sourced CFO and CBO roles. Prior to owning her own firm, Mariam was the Chief Financial Officer of Sucampo Pharmaceuticals. (NASDAQ: SCMP). Her years of experience include strategic planning, investor relations, human resources, internal controls for public and private companies, SOX compliance, and oversite of human resources and information technology. Mariam has significant SEC reporting, tax, acquisition, technical accounting, budgeting, treasury, operations and project management experience. She has a Masters in Taxation from Old Dominion University, a B.A. in Accounting from Texas Tech University, and is a member of the AICPA and TSCPA.

John Kaiser

John Kaiser

Chief Business Officer

Mr. Kaiser serves as Cerecor's Chief Business Officer with responsibilities for corporate strategy, strategic marketing and business development and led the company to acquire both CERC-301 and CERC-501 in 2013 and 2015 respectively. Prior to joining Cerecor, Mr. Kaiser founded Denysias Bioscience, LLC, a biopharmaceutical company focused on developing new therapies for neuropsychiatric disorders, where he served as Chief Executive Officer. At the same time, Mr. Kaiser also served as President of Kaiser & Associates Consulting, a boutique consulting firm providing strategic corporate and commercial expertise to the biopharmaceutical industry. From 2008-2009, Mr. Kaiser served as Vice President of Commercial and Business Development at ACADIA Pharmaceuticals Inc. Before ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities in sales, marketing and general management at Eli Lilly and Company in a career of more than 25 years. At Lilly, Mr. Kaiser led the global commercialization efforts of Prozac®, the global strategic marketing efforts for Cymbalta®, and helped drive the commercial success of Zyprexa® internationally. Mr. Kaiser also led the strategic marketing efforts for the company's CNS development portfolio and co-led the development and execution of the company's CNS strategy. Mr. Kaiser is a member of Cerecor's Senior Management Team and currently serves on the Board of Directors of NHTherapeutics. Mr. Kaiser received his B.S. in pharmaceutical sciences from the James L. Winkle College of Pharmacy at the University of Cincinnati.

Investor Relations

Cerecor, Inc.

NASDAQ: CERC Symbol
Price
Change
Volume
Day Range
52 Week Range